Self-management of anticoagulation

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 7, 2008, Pages 979-985

  Levi, Marcel ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Anticoagulant; Self management; Vitamin K antagonist

Indexed keywords

ANTICOAGULANT AGENT; ANTIVITAMIN K; WARFARIN;

ANTICOAGULANT THERAPY; BLEEDING; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DRUG SELF ADMINISTRATION; GENERAL PRACTITIONER; HEALTH CARE COST; HUMAN; INTERMETHOD COMPARISON; INTERNATIONAL NORMALIZED RATIO; LABORATORY TEST; MEDICAL SPECIALIST; PATIENT SAFETY; PATIENT SATISFACTION; PROTHROMBIN TIME; QUALITY OF LIFE; REIMBURSEMENT; RELIABILITY; REVIEW; SELF CARE; SELF EVALUATION; THROMBOEMBOLISM; TREATMENT OUTCOME; AMBULATORY CARE; BLOOD CLOTTING TEST; DOSE RESPONSE; DRUG MONITORING; INSTRUMENTATION; METHODOLOGY;

AMBULATORY CARE; ANTICOAGULANTS; BLOOD COAGULATION TESTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; HUMANS; INTERNATIONAL NORMALIZED RATIO; PATIENT SATISFACTION; SELF CARE; WARFARIN;

EID: 52049094618     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.7.979     Document Type: Review

References (55)

1. Hirsh J, Guyatt G, Albers GW, Schunemann HJ. The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy: Evidence-Based Guidelines. Chest 126(3 Suppl.), 172S-173S (2004).
2. AnseU J, Hirsh J, Poller L, Bussey H, Jacobson A, Hylek E. The Pharmacology and Management of the Vitamin K Antagonists: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126(3 Suppl.), 204S-223S (2004).
3. Mannucci PM, Levi M. Prevention and treatment of major blood loss. N. Engl. J. Med. 356(22), 2301-2311 (2007).
4. Hirsh J. Oral anticoagulant drugs. N. Engl. J. Med. 324(26), 1865-1875 (1991).
5. O'Reilly RA, Aggeler PM. Determinants of the response to oral anticoagulant drugs in man. Pharmacol. Rev. 22(1), 35-96 (1970).
6. Fairweather RB, Ansell J, van den Besselaar AM et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of oral anticoagulant therapy. Arch. Pathol Lab. Med. 122(9), 768-781 (1998).
7. Cortelazzo S, Finazzi G, Viero P et al. Thrombotic and hemorrhagic complications in patients with mechanical heart valve prosthesis attending an anticoagulation clinic. Thromb. Haemost. 69(4), 316-320 (1993).
8. Errichetti AM, Holden A, Ansell J. Management of oral anticoagulant therapy. Experience with an anticoagulation clinic. Arch. Intern. Med. 144(10), 1966-1968 (1984).
9. Ansell JE, Patel N, Ostrovsky D, Nozzolillo E, Peterson AM, Fish L. Long-term patient self-management of oral anticoagulation. Arch. Intern. Med. 155(20), 2185-2189 (1995).
10. van der Meer J, Hillege HL, Kootstra GJ et al.; The CABADAS Research Group of the Interuniversity Cardiology Institute of The Netherlands. Prevention of one-year vein-graft occlusion after aortocoronary-bypass surgery: a comparison of low-dose aspirin, low-dose aspirin plus dipyridamole, and oral anticoagulants. Lancet 342(8866), 257-264 (1993).
11. Cannegieter SC, Rosendaal FR, Wintzen AR, van der Meer FJ,Vandenbroucke JP, Brier E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N. Engl. J. Med. 333(1), 11-17 (1995).
12. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group. Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 343(8896), 499-503 (1994).
13. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial. Lancet 360(9327), 109-113 (2002).
14. Poller L, Shiach CR, MacCallum PK et al. Multicentre randomised study of computerised anticoagulant dosage. European Concerted Action on Anticoagulation. Lancet 352(9139), 1505-1509 (1998).
15. Levi M. Haemostasis and thrombosis: new developments in treatment strategies. Neth. J. Med. 61(5 Suppl.), 8-12 (2003).
16. Levi M, Hovingh GK, Cannegieter SC, Vermeulen MR, Buller HR, Rosendaal FR. Bleeding in patients receiving vitamin K-antagonists that would have been excluded from trials on which the indication for anticoagulation was based. Blood 111(9), 4471-4476 (2008).
17. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, Levi M, Sturk A. Improvement in the regulation of the vitamin K antagonist acenocoumarol after a standard initial dose regimen: prospective validation of a prescription model. J. Thromb. Thrombolysis PMID: 18270659 (2008) (Epub ahead of print).
18. van Geest-Daalderop JH, Hutten BA, Sturk A, Levi MM. Age and first INR after initiation of oral anticoagulant therapy with acenocoumarol predict the maintenance dosage. J. Thromb. Thrombolysis 15(3), 197-203 (2003).
19. van Geest-Daalderop JH, Hutten BA, Pequeriaux NC, Haas FJ, Levi M, Sturk A. The influence on INRs and coagulation factors of the time span between blood sample collection and intake of phenprocoumon or acenocoumarol: Consequences for the assessment of the dose. Thromb. Haemost. 98(4), 738-746 (2007).
20. Kok G, Van DB, Mullen PD. Effectiveness of health education and health promotion: meta-analyses of effect studies and determinants of effectiveness. Patient Educ. Couns. 30(1), 19-27 (1997).
21. Leaning KE, Ansell JE. Advances in the monitoring of oral anticoagulation: Point-of-care testing, patient self-monitoring, and patient self-management. J. Thromb. Thrombolysis 3(4), 377-383 (1996).
22. Tripodi A, Chantarangkul V, Clerici M, Negri B, Mannucci PM. Determination of the international sensitivity index of a new near-patient testing device to monitor oral anticoagulant therapy. Thromb. Haemost. 78(2), 855-858 (1997).
23. Kitchen S, Preston FE. Monitoring oral anticoagulant treatment with the TAS near-patient test system: comparison with conventional thromboplastins. J. Clin. Pathol. 50(11), 951-956 (1997).
24. Ansell JE. Empowering patients to monitor and manage oral anticoagulation therapy. JAMA 281(2), 182-183 (1999).
25. Fitzmaurice DA, Gardiner C, Kitchen S, Mackie I, Murray ET, Machin SJ. An evidence-based review and guidelines for patient self-testing and management of oral anticoagulation. Br. J. Haematol. 131(2), 156-165 (2005).
26. Oberhardt BJ, Dermott SC, Taylor M, Alkadi ZY, Abruzzini AF, Gresalfi NJ. Dry reagent technology for rapid, convenient measurements of blood coagulation and fibrinolysis. Clin. Chem. 37(4), 520-526 (1991).
27. Kapiotis S, Quehenberger P, Speiser W. Evaluation of the new method Coaguchek for the determination of prothrombin time from capillary blood: comparison with Thrombotest on KC-1. Thromb. Res. 77(6), 563-567 (1995).
28. Machin SJ, Mackie IJ, Chitolie A, Lawrie AS. Near patient testing (NPT) in haemostasis - a synoptic review. Clin. Lab. Haematol. 18(2), 69-74 (1996).
29. van den Besselaar AM, Breddin K, Lutze G et al. Multicenter evaluation of a new capillary blood prothrombin time monitoring system. Blood Coagul. Fibrinolysis 6(8), 726-732 (1995).
30. Cromheecke ME, Levi M, Colly LP et al. Oral anticoagulation self-management and management by a specialist anticoagulation clinic: a randomised cross-over comparison. Lancet 356, 97-102 (2000).
31. White RH, McCurdy SA, Woodruff DEJ, Leftgoff L. Home prothrombin time monitoring after the initiation of warfarin therapy. A randomized, prospective study. Ann. Intern. Med. 111 (9), 730-737 (1989).
32. Beyth RJ, Landefeld CS. Prevention of major bleeding in older patients treated with warfarin: results of a randomized trial. J. Gen. Intern. Med. 12, 66 (1997).
33. Horstkotte D, Piper C, Wiemer M. Optimal frequency of patient monitoring and intensity of oral anticoagulation therapy in valvular heart disease. J. Thromb. Thrombolysis 5(Suppl. 1), S19-S24 (1998).
34. Cosmi B, Palareti G, Carpanedo M et al. Assessment of patient capability to self-adjust oral anticoagulant dose: a multicenter study on home use of portable prothrombin time monitor (COAGUCHECK). Haematologica 85(8), 826-831 (2000).
35. Sidhu P, O'Kane HO. Self-managed anticoagulation: results from a two-year prospective randomized trial with heart valve patients. Ann. Thorac. Surg. 72(5), 1523-1527 (2001).
36. Horstkotte D, Piper C, Wiemer M, Schulte HD, Schultheiss HP. Improvement of prognosis by home prothrombin estimation in patients with life-long anticoagulant therapy. Eur. Heart J. 17 (Suppl.), 230 (1996).
37. Watzke HH, Forberg E, Svolba G, Jimenez-Boj E, Krinninger B. A prospective controlled trial comparing weekly self-testing and self-dosing with the standard management of patients on stable oral anticoagulation. Thromb. Haemost. 83(5), 661-665 (2000).
38. Hasenkam JM, Kimose HH, Knudsen L et al. Self management of oral anticoagulant therapy after heart valve replacement. Eur. J. Cardio-Thorac. Surg. 11(5), 935-942 (1997).
39. Sawicki PT; Working Group for the Study of Patient Self-Management of Oral Anticoagulation. A structured teaching and self-management program for patients receiving oral anticoagulation: a randomized controlled trial. JAMA 281(2), 145-150 (1999).
40. Koertke H, Mainami K, Breymann T. INR self-management following mechanical heart valve replacement. Are education level and therapeutic compliance connected? J. Thromb. Thrombolysis 9(Suppl.), S41-S46 (2000).
41. Gadisseur AP, Breukink-Engbers WG, van der Meer FJ, van den Besselaar AM, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in The Netherlands: a randomized clinical trial. Arch. Intern. Med. 163(21), 2639-2646 (2003).
42. Fitzmaurice DA, Murray ET, Gee KM, Allan TF, Hobbs FD. A randomised controlled trial of patient self-management of oral anticoagulation treatment compared with primary care management. J. Clin. Pathol. 55(11), 845-849 (2002).
43. Sunderji R, Gin K, Shalansky K et al. A randomized trial of patient self-managed versus physician-managed oral anticoagulation. Can. J. Cardiol. 20(11), 1117-1123 (2004).
44. Menendez-Jandula B, Souto JC, Oliver A et al. Comparing self-management of oral anticoagulant therapy with clinic management: a randomized trial. Ann. Intern. Med. 142(1), 1-10 (2005).
45. Voller H, Glatz J, Taborski U, Bernardo A, Dovifat C, Heidinger K. Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study). Z. Kardiol. 94(3), 182-186 (2005).
46. Eitz T, Schenk S, Fritzsche D et al. International normalized ratio self-management lowers the risk of thromboembolic events after prosthetic heart valve replacement. Ann. Thorac. Surg. 85 (3), 949-954 (2008).
47. Levi M, de BT, van der Meer FJ, Cromheecke ME, de MB. Self-monitoring and self dosing of oral anticoagulant therapy with vitamin K antagonists. Ned. Tijdschr. Geneeskd. 145(48), 2313-2317 (2001).
48. Matchar DB, Jacobson AK, Edson RG et al. The impact of patient self-testing of prothrombin time for managing anticoagulation: rationale and design of VA Cooperative Study #481 - the Home INR Study (THINRS). J. Thromb. Thrombolysis 19(3), 163-172 (2005).
49. Gadisseur AP, Kaptein AA, Breukink-Engbers WG, van der Meer FJ, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J. Thromb. Haemost. 2(4), 584-591 (2004).
50. Siebenhofer A, Rakovac I, Kleespies C, Piso B, Didjurgeit U. Self-management of oral anticoagulation in the elderly: rationale, design, baselines and oral anticoagulation control after one year of follow-up. A randomized controlled trial. Thromb. Haemost. 97(3), 408-416 (2007).
51. Siebenhofer A, Berghold A, Sawicki PT. Systematic review of studies of self-management of oral anticoagulation. Thromb. Haemost. 91(2), 225-232 (2004).
52. Heneghan C, Onso-Coello P, Garcia-Alamino JM, Perera R, Meats E, Glasziou P. Self-monitoring of oral anticoagulation: a systematic review and meta-analysis. Lancet 367(9508), 404-411 (2006).
53. Anderson DR, Harrison L, Hirsh J. Evaluation of a portable prothrombin time monitor for home use by patients who require long-term oral anticoagulant therapy. Arch. Intern. Med. 153(12), 1441-1447 (1993).
54. Taborski U, Wittstamm FJ, Bernardo A. Cost-effectiveness of self-managed anticoagulant therapy in Germany. Semin. Thromb. Hemost. 25(1), 103-108 (1999).
55. Jowett S, Bryan S, Murray E et al. Patient self-management of anticoagulation therapy: a trial-based cost-effectiveness analysis. Br. J. Haematol. 134(6), 632-639 (2006).